La Jolla Pharmaceutical Company. (NASDAQ: LJPC) 69% HIGHER; announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE